

## LIBERIA Support for Measles Follow up Campaign

This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Liberia														
<b>2. Grant number:</b> 18-LBR-36a-X / 18-LBR-37a-Y														
<b>3. Date of Decision Letter:</b> 21 July 2017														
<b>4. Date of the Partnership Framework Agreement:</b> 19 August 2013														
<b>5. Programme title:</b> New Vaccine Support (NVS), Measles follow-up campaign														
<b>6. Vaccine type:</b> Measles														
<b>7. Requested product presentation and formulation of vaccine:</b> 10 lyophilised														
<b>8. Programme duration<sup>1</sup>:</b> 2018														
<b>9. Programme Budget (indicative):</b> (subject to the terms of the partnership framework agreement, if applicable)														
	2018	Total <sup>2</sup>												
Programme Budget (US\$)	248,500	248,500												
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable														
<b>11. Gavi Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>3</sup>														
Type of supplies to be purchased with Gavi funds in each year	2018													
Number of vaccines doses	839,500													
Annual Amounts (US\$)	248,500													
<p>For information and reference, the related Injection Safety Devices to be purchased under Gavi funds for 2017 shall be included in a separate Decision Letter (Grant Number 17-LBR-32a-X &amp; 18-LBR-32a-X):</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">New Vaccine Support (NVS), Measles, 10 dose(s) per vial, LYOPHILISED, Campaign</th> <th style="text-align: center;">2017</th> <th style="text-align: center;">2018</th> </tr> </thead> <tbody> <tr> <td>Number of AD syringes</td> <td></td> <td style="text-align: center;">847,400</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> <td style="text-align: center;">94,100</td> </tr> <tr> <td>Number of safety boxes</td> <td></td> <td style="text-align: center;">10,375</td> </tr> </tbody> </table>			New Vaccine Support (NVS), Measles, 10 dose(s) per vial, LYOPHILISED, Campaign	2017	2018	Number of AD syringes		847,400	Number of re-constitution syringes		94,100	Number of safety boxes		10,375
New Vaccine Support (NVS), Measles, 10 dose(s) per vial, LYOPHILISED, Campaign	2017	2018												
Number of AD syringes		847,400												
Number of re-constitution syringes		94,100												
Number of safety boxes		10,375												

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the amount that Gavi has approved.

Annual Amounts for injection safety devices for Vaccine (US\$)		43,500
<b>12. Procurement agency:</b> UNICEF.		
<b>13. Self-procurement:</b> Not applicable		
<b>14. Co-financing obligations:</b> Not applicable		
<b>15. Operational support for the campaign:</b>		
		2018
Grant amount (US\$)		501,000
<b>16. Additional reporting requirements:</b> Country shall deliver the following documents by the specified due dates.		
Reports and other information	Due dates	
In accordance with applicable Gavi processes, Liberia shall report on programmatic and financial performance.	To be agreed with Secretariat	
Supplementary Immunisation Activity (SIA) technical report	Within 3 months of end of campaign	
Post campaign coverage survey report	As soon as available	
<b>17. Financial clarifications:</b> Not applicable		
<b>18. Other conditions:</b> As a condition to Gavi's support for measles, Liberia will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.		

On behalf of Gavi



Barry Greene  
Managing Director  
Finance & Operations  
The GAVI Alliance

*H.K.* Hind Khatib-Othman  
Managing Director, Country Programmes

21 July 2017